Monday, May 22, 2017

Skolkovo partners with BioMarin to fund biomedical research center

Last week, the Skolkovo Fund signed an agreement of cooperation with U.S.-based biomedical company BioMarin during the 2014 BIO International Biomedical Technology Congress in San Diego.

Skolkovo's agreement with BioMarin calls for the establishment of a research and development center in Russia to be funded by both Skolkovo and government agencies.

The center will allow BioMarin researchers to continue their work on diagnosing rare diseases in conjunction with scientists from the Skolkovo Institute of Science and Technology.

"We are delighted that one of the leaders of the biotechnology industry, BioMarin, became part of Skolkovo's innovation ecosystem," Skolkovo Vice President Cyril Kai said. "We hope that our cooperation will successfully develop and implement Skolkovo and Russian innovative treatments for orphan diseases that were previously considered untreatable."

BioMarin General Manager Andrei Harevsky said the joint projects could lead to innovative diagnostic tools for rare diseases, ultimately resulting in the development of advanced biomedical technologies.

"Collaboration with academic and government institutions at Skolkovo's site will be useful for the development of the Russian medical science and practical assistance to patients with rare diseases," Harvesky said.

This year's BIO conference was attended by more than 15,000 members of the biomedical technology industry from across 65 countries. The Skolkovo Fund was represented at the conference through exhibits by seven companies with which the organization has active partnerships.